Pfizer & BioNTech report plans for COVID vaccine

Pfizer and BioNTech report the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.

Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from the FDA.